In a recent PharmaBoardroom interview, CEO & Co-founder Thomas Fessard shares how SpiroChem evolved from a catalog supplier into a global discovery partner tackling the most complex challenges in modern medicinal chemistry.
Embracing Scientific Complexity
“Complexity is our everyday business” Thomas explains. This philosophy drives our work across next-generation modalities — from macrocycles and peptides to antibody–drug conjugates (ADCs).
Strategic Global Growth
He also highlights our expansion to North America through the acquisition of Cyclenium, strengthening our ability to support biotech and pharma innovators worldwide.
Value Beyond Cost
Thomas underscores that true CRO value lies in scientific outcomes and robust solutions, not hourly rates — a principle at the heart of SpiroChem’s approach.
👉 Read the full interview: PharmaBoardroom – Thomas Fessard, CEO & Co-founder, SpiroChem
